Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real‐world Canadian dermatology clinics: a multicenter retrospective study

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-3083|32|1|e32-e34

ISSN： 0926-9959

Source： JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.32, Iss.1, 2018-01, pp. : e32-e34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Safety, efficacy, and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : e163-e163

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 509-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival rates of biological therapies for psoriasis treatment in real‐world clinical practice: A Canadian multicentre retrospective study

By  

AUSTRALASIAN JOURNAL OF DERMATOLOGY, Vol. 59, Iss. 1, 2018-02 ,pp. : e11-e14

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1148-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 3, 2018-03 ,pp. : 340-346

John Wiley & Sons Inc

Access to resources Recommend Favorite